WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII - News), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches. The rxRNA™ compounds are designed specifically for therapeutic use and contain many of the properties needed to develop RNAi-based drugs.
Commenting on today's news, Noah D. Beerman, President and Chief Executive Officer of RXi Pharmaceuticals, stated, "We are honored to receive this prestigious award. RXi has built a comprehensive RNAi therapeutic platform based on innovative technology that we are using to advance internal therapeutic programs as well as those of our partners and collaborators. RXi's therapeutic platform consists of rxRNA™ compounds optimized for therapeutic applications and advanced delivery technologies for both local and systemic delivery. For these accomplishments, RXi has been recognized with the Frost & Sullivan RNAi Technology Innovation of the Year Award."
Frost & Sullivan's Technology Innovation Award is bestowed upon a company (or individual) that has carried out new research which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This award recognizes the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.
A full copy of the report is available at: www.rxipharma.com
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi compounds and potential delivery methods. RXi uses its own version of RNAi compounds -- rxRNA™ -- designed specifically for therapeutic use and contain many of the properties needed to move RNAi-based drugs into the clinic. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position in RNAi chemistry and delivery. www.rxipharma.com
No comments:
Post a Comment